添加羟基脲(羟基脲)可增强氟达拉滨/阿糖胞苷为基础的挽救方案对急性髓系白血病的疗效
在复发/难治性急性髓系白血病(AML)中,SAMHD1酶介导对阿糖胞苷(ara-C)和氟达拉滨(F-ara-A)的耐药。本研究在AML细胞系、原代AML细胞和免疫健全AML小鼠模型中证实,羟基脲(HU)通过抑制SAMHD1协同增强ara-C、F-ara-A及FLA方案的细胞毒性,并显著增加活性三磷酸代谢物;白血病SAMHD1蛋白表达与FLA治疗的难治性AML患者总生存负相关。作者认为加用HU可提高FLA方案的疗效,并需开展临床试验验证其安全性和有效性。
要点
- HU以SAMHD1依赖方式协同增强ara-C、F-ara-A及FLA在AML细胞系、原代AML细胞和免疫健全AML小鼠模型中的细胞毒性。
- HU显著增加FLA组合中ara-C和F-ara-A的活性三磷酸代谢物。
- 白血病SAMHD1蛋白表达与FLA治疗的难治性AML患者总生存呈负相关。
核心结论
- 研究提示加用羟基脲可提高以FLA为基础的方案疗效,并需开展临床试验在复发/难治性AML患者中检验该组合的安全性和有效性。
研究设计与样本
- 研究在AML细胞系、原代AML细胞和免疫健全AML小鼠模型中进行,并分析了一组接受FLA治疗的难治性AML患者队列中白血病SAMHD1蛋白表达与总生存的相关性。
主要发现
- HU以SAMHD1依赖方式协同增强ara-C、F-ara-A和FLA诱导的细胞毒性。
- HU显著增加FLA组合中ara-C和F-ara-A的活性三磷酸代谢物。
- 白血病SAMHD1蛋白表达与FLA治疗的难治性AML患者总生存呈负相关。
临床怎么用
- 作者认为加用HU可提高FLA为基础方案的疗效,并需开展临床试验在复发/难治性AML患者中检验该组合的安全性和有效性。
局限性
- 原文在结论中提出需开展临床试验以检验该组合在复发/难治性AML患者中的安全性和有效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite intensive treatment, patients with relapsed or refractory acute myeloid leukaemia (AML) have a dismal prognosis. A cornerstone therapy for relapsed/refractory AML is a combination of fludarabine (F-ara-A) and cytarabine (ara-C), so-called FLA. As the enzyme SAMHD1 mediates resistance to both ara-C and F-ara-A, we investigated whether SAMHD1 inhibition via hydroxyurea (hydroxycarbamide; HU) could improve FLA efficacy. Here, we show that HU synergistically enhanced ara-C-, F-ara-A- and FLA-induced cytotoxicity in an SAMHD1-dependent manner in AML cell lines, primary AML cells and an immunocompetent AML mouse model. Mechanistically, HU significantly increased the active metabolite triphosphates of ara-C and F-ara-A in FLA combinations. Furthermore, leukaemic SAMHD1 protein expression negatively correlated with overall survival in a cohort of FLA-treated refractory AML patients. Our findings suggest that the addition of HU improves the efficacy of FLA-based regimens and warrant clinical trials to test the safety and efficacy of this combination in patients with relapsed/refractory AML.
引用
- Lilienthal I, Tao S, Nilsson C, et al. Addition of hydroxyurea (hydroxycarbamide) enhances the efficacy of fludarabine/cytarabine-based salvage regimens against acute myeloid leukaemia. Br J Haematol. 2025. PMID: 41014199. doi:10.1111/bjh.70180
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。